Related Experiment Videos
Recent data on hypertension and progressive renal disease
1Malpighi Department of Nephrology, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Journal of Human Hypertension
|October 1, 1996
Summary
Arterial hypertension accelerates kidney disease progression. The AIPRI trial demonstrated that benazepril, an ACE-inhibitor, protected patients with mild-to-moderate renal disease from worsening kidney insufficiency.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Arterial hypertension is a known risk factor for the progression of non-diabetic primary renal disease.
- Hypertension can also contribute to the development of atheromatous renovascular disease.
- Renal failure in elderly patients with chronic hypertension may stem from atheromatous renovascular disease, including renal artery stenosis and cholesterol microembolization.
Purpose of the Study:
- To evaluate the renoprotective effects of ACE-inhibition in patients with mild-to-moderate renal disease.
- To investigate the role of atheromatous renovascular disease in the progression of renal failure in hypertensive patients.
Main Methods:
- The study involved the AIPRI trial (ACE-inhibition in the progression of renal insufficiency).
- Patients received the ACE-inhibitor benazepril.
- The trial assessed the progression of renal insufficiency in patients with mild-to-moderate renal disease.
Main Results:
- Benazepril demonstrated a protective effect against the progression of renal insufficiency in the studied patient cohort.
- Clinical observations suggest a link between atheromatous renovascular disease and renal failure in elderly hypertensive individuals.
Conclusions:
- ACE-inhibitor therapy, specifically benazepril, can offer protection against renal insufficiency progression in patients with mild-to-moderate renal disease.
- Atheromatous renovascular disease is implicated as a significant contributor to progressive renal failure in aged patients with long-standing hypertension.